Results from AGMT_MM-1 published
In September, two publications on the AGMT_MM-1 study were published....
BREAKING NEWS:
Further information will follow…
Prof. Dr. Richard Greil
Head of the IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Dr. Simon P. Gampenrieder
IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Dr. Gabriel Rinnerthaler
IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer, Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Luca Gianni MD
Michelangelo Foundation, Milan, Italy
Dr. Iosifina Foskolou
Prof. R. Johnson’s Group, Evelyn Trust Patrick Sissons Fellow, Darwin College, Cambridge, United Kingdom; Jonas Söderquists Scholar, Karolinska Institutet, Stockholm, Sweden
Prof. Pedro Romero MD
Associate Director, Department of Fundamental Oncology, Lausanne University Hospital (CHUV), Faculty of Biology and Medicine, University of Lausanne, Switzerland
Berna Özdemir MD PhD
Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland
Onur Boyman MD
Professor and Chair of Clinical Immunology, Deputy Dean of Faculty of Medicine, University of Zurich; Director, Department of Immunology, University Hospital Zurich, Switzerland
Prof. Alberto Mantovani MD
Humanitas University, Scientific Director, Istituto Clinico Humanitas IRCCS Milan, Italy
William Harvey Research Institute, London
Marie-Agnès Doucey PhD MER
University of Lausanne and Director & Project Team Leader – Discovery, Ichnos Sciences SA, Lausanne, Switzerland
Dr. Roberto Salgado
Department of Pathology, GZA-ZNA Antwerp, Belgium; Division of Research, Peter Mac Callum Cancer Center, Melbourne, Australia
Karen Willard-Gallo MD PhD
Head, Molecular Immunology Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Prof. Dr. Barbara Seliger
Director of the Institute for Medical Immunology, Martin Luther University, Medical Faculty, Halle, Germany
Giuseppe Curigliano MD PhD
University of Milan, Director, New Drugs and Early Drug Development for Innovative Therapies Division, European Institute of Oncology, Milan, Italy
Marco Gerlinger MD FRCP
Medical Oncologist and Research Group Leader, Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, Institute of Cancer Research, London, United Kingdom
Dr. Laszlo G. Radvanyi PhD
President and Scientific Director, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
Dr. John Maher
Consultant and Senior Lecturer in Immunology, King’s College London, United Kingdom
12:30 – 13:30 Welcome & Business Lunch
13:30 – 13:35 Introduction
Richard Greil, Salzburg
13:35 – 14:25 The clinical point of view
Oxford-style debate: Immunotherapy in breast cancer: failure or magic bullet?
Simon Gampenrieder/ Gabriel Rinnerthaler (Salzburg)
Predictive biomarkers in breast cancer immunotherapy trials
Luca Gianni (Milan)
14:25 – 15:15 Metabolism and metabolomics
Hypoxia-inducible metabolites shape T cell fate
Iosifina Foskolou (Cambridge)
Navigating metabolic pathways to enhance antitumor immunity and immunotherapy
Pedro Romero (Lausanne)
15:15 – 15:45 Coffee break
15:45 – 16:35 Influence on immunogenicity
…by sex hormones
Berna C. Özdemir (Lausanne)
…epigenetic regulation
Onur Boyman (Zurich)
16:35 – 17:30 The innate immune system
Innate Immunity , inflammation and cancer: double edged swords
Alberto Mantovani (Milan)
Pharmacological re-programming of CD144 pro-metastatic monocytes in human breast cancer
Marie-Agnes Doucey (Lausanne)
17:30 – 18:30 Panel discussion
19:00 Dinner
08:30 – 10:00 The adaptive immune system
PD-L1 vs. TILs: analytic and diagnostic issues
Roberto Salgado (Antwerp)
Tertiary lymphoid structures: Phenotypic, genotypic and functional features and their link with the response to cancer immunotherapy
Karen Willard-Gallo (Brussels)
MHC class I loss in breast cancer
Barbara Seliger (Halle)
10:00 – 10:30 Coffee break
10:30 – 12:10 New treatment strategies
Immunotherapy strategies beyond PD1/PD-L1 inhibition
Giuseppe Curigliano (Milan)
Bispecific antibodies in the treatment of solid tumors
Marco Gerlinger (London)
Adoptive T cell therapy for metastatic melanoma: Lessons learned and implications for breast cancer
Laszlo G. Radvanyi (Toronto)
CAR T-Cells in breast cancer
John Maher (London)
12:10 – 12:55 Panel-Discussion
Closing Remarks
Richard Greil (Salzburg)
13:00 – 14:00 Business Lunch & Farewell
We look forward to your registration, but we would like to point out that this conference is not open to the public. After your registration your entries will be checked by us, followed by information about your requested participation.
4th SALZBURG BREAST CANCER TALK – Mastering translational Immuno-Oncology has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 8 European CME credits (ECMEC®s).
Prof. Dr. Richard Greil
Dr. Simon P. Gampenrieder
Dr. Gabriel Rinnerthaler
Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)
in Kooperation mit
Cancer Cluster Salzburg | www.cancercluster-salzburg.at
In September, two publications on the AGMT_MM-1 study were published....
01.- 02.03.2019 Salzburg — MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY...
02.- 03.03.2018 Salzburg — MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY...
10.- 11.02.2017 Salzburg — MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY...